Clinical trials on 200 patients (in the U.S.) and 500 (internationally) are "underway or are about to start," Viratek reports. Studies, which were okayed when FDA lifted the clinical hold on the product, are aimed at lymphadenopathy syndrome (LAS) patients. Sales of ribavirin for RSV (respiratory syncytial virus) declined sharply in 1987: down to $1.4 mil. from $10.9 mil. the year before.
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.